Viridian Therapeutics (VRDN) Stock Forecast & Price Target

Viridian Therapeutics has demonstrated a positive trajectory with the release of encouraging data from the phase 3 THRIVE trial, which achieved statistical significance across all primary and secondary endpoints, aligning with the efficacy data of Tepezza. This trial outcome highlights the potential effectiveness of Veligrotug, potentially capturing a larger share of the thyroid eye disease (TED) market, particularly with the anticipated launch of a subcutaneous administration option. Additionally, the M&A interest in Horizon Therapeutics, culminating in a significant acquisition offer, further reinforces the growth opportunities within the TED market, suggesting a favorable environment for Viridian's advancement and the commercialization of its product candidates.

Viridian Therapeutics Inc faces significant challenges related to the high costs associated with the manufacturing of its monoclonal antibodies, particularly for its lead product candidate, Veligrotug. Additionally, recent clinical data from the THRIVE study raised concerns regarding increased incidences of adverse events such as muscle spasms and headaches, which could affect patient uptake and overall product perception. These factors, combined with potential difficulties in establishing a reliable clinical and commercial supply chain with third-party manufacturers, contribute to an overall negative outlook for the company’s stock.